This joint ERS and ATS webinar offers a unique transatlantic comparison of how the 2025 bronchiectasis guidelines are implemented in U.S. and European practice, highlighting differences in healthcare systems, access, and real-world management.
The 2025 ERS bronchiectasis guidelines represent a paradigm shift in management, introducing new strong recommendations for long-term macrolides, inhaled antibiotics, and guidance against routine use of certain therapies. However, there is currently no ATS guideline, creating potential divergence in how US and European clinicians interpret and implement this evidence. Furthermore, the field is rapidly evolving toward precision medicine approaches based on endophenotypes and treatable traits. This webinar addresses the urgent need to align transatlantic perspectives, clarify how medication approval processes, reimbursement structures, and access issues shape real-world practice, and identify areas of convergence and divergence. Understanding these differences is essential for harmonising global care standards, informing future joint guideline development, and ultimately improving outcomes for bronchiectasis patients worldwide.